| __timestamp | Grifols, S.A. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 660772000 | 49315000 |
| Thursday, January 1, 2015 | 736435000 | 75043000 |
| Friday, January 1, 2016 | 775266000 | 83749000 |
| Sunday, January 1, 2017 | 860348000 | 122682000 |
| Monday, January 1, 2018 | 814775000 | 207761000 |
| Tuesday, January 1, 2019 | 942821000 | 284812000 |
| Wednesday, January 1, 2020 | 985616000 | 317875000 |
| Friday, January 1, 2021 | 1061508000 | 282660000 |
| Saturday, January 1, 2022 | 1190423000 | 451421000 |
| Sunday, January 1, 2023 | 1254234000 | 481871000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Sarepta Therapeutics, Inc. and Grifols, S.A. from 2014 to 2023. Over this period, Grifols consistently outpaced Sarepta in SG&A spending, with a notable increase of approximately 90% from 2014 to 2023. In contrast, Sarepta's SG&A expenses surged by nearly 880%, reflecting its aggressive growth strategy.
By 2023, Grifols' SG&A expenses reached a peak, nearly doubling from 2014, while Sarepta's expenses grew almost tenfold. This disparity highlights Grifols' established market presence and Sarepta's rapid expansion efforts. Such insights are invaluable for investors and industry analysts seeking to understand the strategic priorities and operational scales of these pharmaceutical giants.
Who Optimizes SG&A Costs Better? Zoetis Inc. or Sarepta Therapeutics, Inc.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Insmed Incorporated vs Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. vs Walgreens Boots Alliance, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Sarepta Therapeutics, Inc. vs TG Therapeutics, Inc.
Sarepta Therapeutics, Inc. or MorphoSys AG: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs Viridian Therapeutics, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Sarepta Therapeutics, Inc. or Evotec SE
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Opthea Limited
Who Optimizes SG&A Costs Better? Grifols, S.A. or Novavax, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs Amphastar Pharmaceuticals, Inc.